Navigation Links
The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
Date:9/18/2007

WHITE PLAINS, N.Y., Sept. 18 /PRNewswire/ -- Millennium Pharmaceuticals and Johnson & Johnson have reported that an interim analysis of a large, randomized, international Phase III trial comparing melphalan-prednisone (MP) with MP in combination with Velcade(R) (bortezomib) showed that the patients treated on the Velcade arm did better. These patients, who are not eligible for a stem cell transplant, experienced statistically significant benefit in terms of time-to-disease progression, complete response rate, progression-free survival and overall survival. Patients treated on the MP arm of the trial have the opportunity to switch over to the Velcade arm.

Detailed results from this trial will be presented at the American Society of Hematology annual meeting in early December.

"This is extremely encouraging news for myeloma patients," said Bart Kamen, M.D., Ph.D., the Society's chief medical officer. "However, while these results are very exciting, the Society reminds patients not to make any changes in their treatment regimen without speaking to their doctor first."

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center st
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
2. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
3. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
4. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
5. Major Gene Study Uncovers Secrets of Leukemia
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
9. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
10. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
11. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015  The onset of puberty can make young athletes ... and thus more inclined toward a variety of injuries. ... body,s center of gravity is altered. It,s a period of ... quickly than the rest of the body and, in some ... year. And while these sudden changes are a natural part ...
(Date:3/6/2015)... 2015   Hospira, Inc. (NYSE: HSP ... (FDA) on today,s FDA approval of the first biosimilar in ... watershed moment for improving patient access to safe, effective and ... biosimilars, Hospira has seen first-hand the positive impact of biosimilars ... these early stages of the development of a pathway for ...
(Date:3/6/2015)... Washington , 6. März 2015 /PRNewswire/ ... von Röntgenstrahlen, feierte auf dem European Congress ... , Österreich, die 1.000. Installation seines ... Logo - http://photos.prnewswire.com/prnh/20150304/179432LOGO ... Dosimeter, der in Echtzeit Informationen über die ...
Breaking Medicine Technology:Puberty can result in variety of athletic injuries 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 3Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 2Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 3
... , SAN DIEGO , July 14 ... the Marketing Authorization Application (MAA) for OraVerse has been accepted ... Kingdom (UK), Germany , Italy , ... and only local anesthesia reversal agent that accelerates the return ...
... 13 Program officials have confirmed that they will announce the ... conference tomorrow in Atlanta .  Georgia Drug Card is being launched ... medications. , , , ... obtain prescription cards at various hospitals, clinics, and other card distribution sites ...
Cached Medicine Technology:Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries 2Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries 3Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries 4
(Date:3/6/2015)... (PRWEB) March 06, 2015 “ Pokemini ” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review and ... game. , Over the last couple of years, mobile ... to the game. For example, Candy Crush allows users to ...
(Date:3/6/2015)... San Jose, California (PRWEB) March 06, 2015 ... cancer is one of the most common forms of ... women worldwide. Breast cancer can be screened through various ... among others. Mammography however remains the gold standard technique ... factors such as cost, time taken for the procedure, ...
(Date:3/6/2015)... New York, New York (PRWEB) March 06, 2015 ... tap dancing’s dazzling days on the grand stage, to the ... Legacy Dancers sparkle throughout with precision toe-tapping numbers and their ... and Karyn Tomczak deliver the rich history of tap dancing ... dance forms to come out of the United States. ...
(Date:3/6/2015)... As the Association of American ... 90,000 doctors by 2025 is updated this week and ... is proactively preparing by analyzing demographics and pursuing viable ... , Several factors including the increasing number of retiring ... the Affordable Care Act and an uneven distribution of ...
(Date:3/6/2015)... 06, 2015 Jvion, the Atlanta-based ... of a Clostridium Difficile (C Diff) predictive use ... Diff use case is the latest in a ... acquired infections, chronic conditions, and individual illnesses. Using ... Diff solution flags at risk individuals to help ...
Breaking Medicine News(10 mins):Health News:A Kawaii Social Game was Featured on NewsWatch Television on February 26, 2015 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 3Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 4Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... small capsule-shaped bacteria. The immune cells which help protect us ... in space travellers and it could be something to do ... (JSC) have been studying how immune cells behave in microgravity ... space on astronauts.// ,It has been found that astronauts ...
... approved the first pocket-sized EKG machine, so small ... ambulances, the emergency room - even a possible ... hand-held computer-based medical device, part of a growing ... equipment. ,Electrocardiograms, also called EKGs or ECGs, ...
... will probably be prescribed cholesterol-lowering drugs as a result ... cautions that the effects of those medications in that ... Cholesterol Education Program guidelines, about 15 million Americans between ... considered candidates taking statin group of drugs for ...
... claim that just by looking at a person's face could ... is that smokers age faster than non smokers.A study by ... genes responsible for a skin enzyme that breaks down collagen ... of the skin and maintains the elasticity of the skin. ...
... have devised that each cigarette cuts on average 12 minutes ... the difference in life expectancy between smokers and non-smokers and ... male smoker might consume in a lifetime. ,The researchers, ... expectancy from a major study of the impact of// smoking ...
... after a couple of drinks is a common problem for ... was a mystery until now.It may support the potentialities of ... College of Medicine and the Mayo Clinic in Minnesota say ... accused.// They found, in a study of healthy young adults, ...
Cached Medicine News:Health News:Immune cells halt round in space 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: